2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Epoxide Hydrolase

Epoxide Hydrolase

Epoxide Hydrolase

Related Products

PDF 0.26 MB

Epoxide hydrolases (EH) present in all living organisms. The mammalian soluble epoxide hydrolase (sEH) is a 120 kDa dimer of two identical 62.5 kDa monomers arranged in an anti-parallel fashion. It is mostly expressed in the liver, kidneys, brain, endothelium, and at lesser levels in other tissues. Inflammation and pain are major components of many disease states. Mammalian sEH inhibition reduces blood pressure, inflammation and pain. The anti-inflammatory activities of sEH inhibitors occur in part through the NF-κB mediated down-regulation of COX2 transcription, resulting in lower production of pro-inflammatory prostaglandins such as PGE2 and PGD2.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-101294
    TPPU
    		Inhibitor 99.15%
    TPPU is a soluble epoxide hydrolase (sEH) inhibitor with IC50 values of 37 and 3.7 nM for monkey and human sEH, respectively.
    TPPU
  • HY-19644
    GSK2256294A
    		Inhibitor 99.84%
    GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease.
    GSK2256294A
  • HY-108570
    AUDA
    		Inhibitor ≥98.0%
    AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively. AUDA has anti-inflammatory activity.
    AUDA
  • HY-135653
    EC5026
    		Inhibitor 98.13%
    EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 shows efficacy for inflammatory and neuropathic pain.
    EC5026
  • HY-114266
    UC-1728
    		Inhibitor 99.88%
    UC-1728 is a potent rabbit soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 2 nM on rabbit liver.
    UC-1728
  • HY-121538A
    CUDA disodium
    		Inhibitor
    CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease.
    CUDA disodium
  • HY-175392
    PROTAC sEH-degrader-3
    		Degrader
    PROTAC sEH-degrader-3 (Compound 1a) is a targeted sEH PROTAC degrader that can selectively degrade sEH in the cytosol without affecting sEH in peroxisomes. PROTAC sEH-degrader-3 degrades sEH through a CRBN-dependent lysosomal pathway rather than the proteasome, with an IC50 of 0.8 nM against hsEH. PROTAC sEH-degrader-3 can inhibit endoplasmic reticulum stress and can be used in the research of inflammation, metabolic diseases, and other diseases related to endoplasmic reticulum stress. (Pink: sEH inhibitor (HY-114266); Black: Linker (HY-W008352); Blue: E3 Ligase Ligand (HY-14658)).
    PROTAC sEH-degrader-3
  • HY-N15524
    Thalictoside
    		Inhibitor
    Thalictoside is found in A. squamosa L. Thalictoside is a sEH inhibitor (IC50: 20.2 µM). Thalictoside exerts anti-osteoporotic effects through an estrogen-like mechanism. Thalictoside can be used in the research of cardiovascular and urinary diseases.
    Thalictoside
  • HY-113974
    trans-AUCB
    		Inhibitor 98.16%
    trans-AUCB (t-AUCB) is a potent, orally active and selective soluble epoxide hydrolase (sEH) inhibitor with IC50s of 1.3 nM, 8 nM, 8 nM for hsEH, mouse sEH and rat sEH, respectively. trans-AUCB has anti-glioma activity.
    trans-AUCB
  • HY-126326
    SWE101
    		Inhibitor 98.99%
    SWE101 (compound 22 b) is a potent soluble epoxide hydrolase (sEH)-P inhibitor with IC50s of 4 μM and 2.8 μM for human and rat sEH-P, respectively. SWE101 does not inhibit neither hydrolase nor phosphatase activity of the mouse sEH.
    SWE101
  • HY-111151
    AR-9281
    		Inhibitor 99.69%
    AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes.
    AR-9281
  • HY-B2117
    Valpromide
    		Inhibitor 99.72%
    Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle.
    Valpromide
  • HY-146696
    mEH-IN-1
    		Inhibitor ≥98.0%
    mEH-IN-1 (Compound 62) is a potent microsomal epoxide hydrolase (mEH) inhibitor with the IC50 of 2.2 nM. The mEH is a mammalian α/β-fold hydrolase enzyme, expressed in almost all tissues, hydrolyzes a wide range of epoxide containing molecules. The mEH is mainly localized in the endoplasmic reticulum (ER) of eukaryotic cells. mEH-IN-1 can be used for the research of preeclampsia, hypercholanemia and cancer.
    mEH-IN-1
  • HY-124063
    BI-1935
    		Inhibitor 98.01%
    BI-1935, a chemical probe, is a potent soluble epoxide hydrolase (sEH) inhibitor. BI-1935 can be used for the research of cardiovascular disease.
    BI-1935
  • HY-128171
    Diflapolin
    		Inhibitor 99.67%
    Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC50s?of? 30 and 170?nM, respectively, and suppressed the activity of isolated sEH (IC50=20?nM).
    Diflapolin
  • HY-121538
    CUDA
    		Inhibitor ≥98.0%
    CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease.
    CUDA
  • HY-155773
    VU534
    		Inhibitor 98.53%
    VU534 is a NAPE-PLD activator, with an EC50 of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC50 of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study [1] .
    VU534
  • HY-148136
    sEH inhibitor-7
    		Inhibitor 99.50%
    sEH inhibitor-7 (compound c-2) is an inhibitor of soluble epoxide hydrolase (sEH) with IC50s of 0.15 μM (mouse sEH) and 6.2 μM (human sEH), respectively. soluble epoxide hydrolase (sEH) plays an important role in the metabolism of endogenous chemical mediators involved in the regulation of blood pressure and inflammation.
    sEH inhibitor-7
  • HY-W097200
    1,3-Dibenzylurea
    		Inhibitor 99.92%
    1,3-Dibenzylurea is an insect growth regulator and a mouse soluble epoxide hydrolase (MsEH) inhibitor.
    1,3-Dibenzylurea
  • HY-W101419
    Ibuprofenamide
    		Inhibitor 98.97%
    Ibuprofenamide (Compound 136) is a potent microsomal epoxide hydrolase (mEH) inhibitor with an IC50 value of 96 μM. Ibuprofenamide is promising for research of preeclampsia, hypercholanemia and cancer.
    Ibuprofenamide
Cat. No. Product Name / Synonyms Application Reactivity